Ananya Kabi¹, Ankita Kabi² and Aroop Mohanty³*

¹MBBS Student, Siksha ‘O’ Anusandhan Medical College, Bhubaneswar, Odisha, India
²Assistant Professor, Department of Emergency Medicine, AIIMS Rishikesh, Uttarakhand, India
³Assistant Professor, Department of Microbiology, AIIMS Gorakhpur, Uttar Pradesh, India

*Corresponding Author: Aroop Mohanty, Assistant Professor, Department of Microbiology, AIIMS Gorakhpur, Uttar Pradesh, India.

Received: September 13, 2021; Published: September 23, 2021

  The COVID-19 pandemic has seen a major upsurge in the cases of Mucormycosis and has led to increased morbidity and mortality worldwide [1]. Indiscriminate use of steroids in patients with uncontrolled diabetes and also use of humidifiers has further worsened the situation [2,3]. The treatment of mucormycosis is done taking into consideration a number of factors and includes the rectification of all the affecting and associated conditions, prompt administration of specific therapy and elimination of all affected tissue by surgery. India being the diabetic capital of the world, harbours a very susceptible population for the development of Mucormycosis. This makes it mandatory on our part to implement rapid correction of metabolic abnormalities in patients with uncontrolled diabetes mellitus [4]. Various studies have postulated the use of sodium bicarbonate with insulin to correct ketoacidosis be it mild or severe in such patients.

References

1. Gupta P., et al. “Concise Information for the Frontline Health care workers in the era of COVID-19- A Review”. Indian Journal of Community Health 32 (2020): 215-224.
2. Kabi A., et al. “Medical management of COVID-19: Treatment options under consideration”. International Journal of Advances in Medicine 7 (2020): 1603-1611.
3. Mohanty A., et al. “Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges: An Indian Perspective”. Journal of Advances in Medicine and Medical Research14 (2020): 10-17.
4. Singh A., et al. “Concomitant Mucormycosis with Aspergillosis in Patients with Uncontrolled Diabetes Mellitus: A Case Series”. Journal of Clinical and Diagnostic Research 2 (2021): 1-3.
5. Mohanty A., et al. “Breaking the mold: a brief review on the diagnostic and treatment approaches of mucormycosis”. International Journal of Otorhinolaryngology and Head and Neck Surgery 7 (2021): 1207-1215.
6. Wiederhold NP. “Phamacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections”. Clinical Pharmacology 8 (2016): 1-8.
7. Reed C., et al. “Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis”. Clinical Infectious Diseases 47 (2008): 364-371.
8. Roilides E., et al. “Pathogenesis and host defence against Mucorales; the role of cytokines and interaction with antifungal drugs”. Mycoses 57 (2014): 40-47.
9. Gebremariam T., et al. “Prophylactic treatment with VT-1161 protects immunosuppressed mice from Rhizopus arzhius var. arrhizus infection”. Antimicrobial Agents and Chemotherapy 59 (2017): 7815-7817.

Citation

Citation: Aroop Mohanty., et al. “Treatment Modalities for Mucormycosis: A Brief Insight".Acta Scientific Pharmacology 2.10 (2021): 24-25.

Copyright

Copyright: © 2020 Aroop Mohanty., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.